New daily shot aims to slow ALS

NCT ID NCT06513546

Not yet recruiting Disease control Sponsor: PLL TX AUSTRALIA PTY LTD Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug, PLL001, in 153 people with ALS. It is given as a daily injection under the skin. The trial is split into two parts: first to check safety, then to see if it slows the disease and helps people live longer. Participants are randomly assigned to get either the drug or a placebo, and neither they nor their doctors will know which they receive.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PLL001 (a combination of small chain fatty acids attached to a poly-lysine backbone, given as a daily injection)
What this could lead to: If it works, this could point toward a treatment that slows ALS progression and improves survival.
What could go wrong: This is an early Phase 1/2 trial with only 153 participants, so results are uncertain. The drug is new and has not been tested in humans before, so safety and effectiveness are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

amyotrophic lateral sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALS AMYOTROPHIC LATERAL SCLEROSIS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.